Antares Therapeutics

Antares Therapeutics

Develops precision oncology therapeutics and pipelines

Overview

Antares Therapeutics focuses on developing precision oncology medicines. It advances targeted cancer therapies by leveraging Scorpion Therapeutics’ discovery platform acquired by Lilly, using its validated pipeline and leadership with deep oncology experience to guide research and development. The company works by identifying cancer-specific targets and creating therapies that act on those targets, followed by clinical validation and eventual commercialization in advanced cancer indications. Its differentiation comes from access to Scorpion’s discovery capabilities, the support and resources of Lilly, and a leadership team with experience in oncology and life sciences, enabling a science-driven approach to push the boundaries of precision medicine. Antares aims to shape the future of precision oncology by delivering transformative treatments that can improve outcomes for cancer patients.

Launched Recently
Significant Headcount Growth

About Antares Therapeutics

Simplify's Rating
Why Antares Therapeutics is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series A

Total Funding

$177M

Headquarters

Boston, Massachusetts

Founded

2025

Simplify Jobs

Simplify's Take

What believers are saying

  • Lead program enters clinical trials in 2026, enabling partnerships like Scorpion's $2.5B Lilly deal.
  • Mutant EGFR inhibitors PFL-721 and PFL-241 licensed to Pierre Fabre for global commercialization.
  • PARP1 inhibitor MOMA-989 partnered with Moma Therapeutics targets combination therapy demand.

What critics are saying

  • Preclinical R&D burns $177M Series A in 24-36 months before clinical data.
  • Most advanced program fails Phase 1 toxicity endpoints in 18-24 months.
  • AstraZeneca launches competing transcription factor drugs ahead of 2026 using 2022 IP.

What makes Antares Therapeutics unique

  • Antares pioneers small molecules targeting undruggable transcription factors in oncology.
  • Leverages Scorpion's computational chemistry and mass spectrometry for novel binding pockets.
  • Advances first-in-class assets from 2022 AstraZeneca transcription factor collaboration.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$177M

Above

Industry Average

Funded Over

1 Rounds

Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$30M
Kalshi
$177M
Antares Therapeutics

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

6%
Business Wire
Jun 11th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...

Pipeline Review
Jun 10th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

BOSTON, MA, USA I June 10, 2025 I Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing.

Recently Posted Jobs

Sign up to get curated job recommendations

Antares Therapeutics is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →